AstraZeneca Cost Cutting, Alnylam Shares Plunge, Regeneron Earnings Beat
AZN Astrazeneca plc
$186.76 -1.39%
View chart & analysis → 
- 1AstraZeneca is on track to reach its annual revenue target of $80 billion by 2030.
- 2Alnylam Pharmaceuticals shares plummeted over 20% following the announcement of $1.13 billion in Amvuttra sales for the third quarter.
- 3Regeneron Pharmaceuticals shares surged 13% on Friday as Dupixent sales grew 35% to $6.5 billion between June and September.
So what's the key point?
AstraZeneca is moving toward its revenue target, while Alnylam's stock fell more than 20% after its sales announcement. On the other hand, Regeneron's stock rose 13% due to increased sales.
Source BioPharma Dive · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.